Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20746672 | 0.86 | PDE2A (0.47) | PDE2AHTR1A | |
| SCHEMBL17898213 | 0.79 | CYP3A4 (0.53) | PDE2AALDH1A1CYP3A4CYP2D6CYP1A2 | |
| SCHEMBL28011532 | 0.76 | PDE2A (0.47) | PDE2AALDH1A1CYP3A4CYP2D6CYP1A2 | |
| SCHEMBL13490514 | 0.75 | CYP3A4 (0.58) | PDE2AALDH1A1CYP3A4CYP2D6CYP1A2 | |
| SCHEMBL171619 | 0.72 | PDE2A (0.55) | PDE2AALDH1A1CYP3A4CYP2D6CYP1A2 | |
| SCHEMBL13490665 | 0.70 | CYP3A4 (0.50) | PDE2AALDH1A1CYP3A4CYP2D6CYP1A2 | |
| SCHEMBL13490502 | 0.69 | PDE2A (0.49) | PDE2AALDH1A1CYP3A4CYP2D6CYP1A2 | |
| SCHEMBL13490598 | 0.69 | CYP2D6 (0.51) | PDE2AALDH1A1CYP3A4CYP2D6CYP1A2 | |
| SCHEMBL28226193 | 0.68 | CYP1A2 (0.66) | ALDH1A1CYP3A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL17898201 | 0.67 | PDE2A (0.45) | PDE2ACYP2D6KCNH2DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562883-B2 | Heterocycles capable of modulating T-cell responses, and methods of using same | NOGRA PHARMA LIMITED (IE) | 2020-02-18 | — | — | US | disclosed |
| US-10562883-B2 | Heterocycles capable of modulating T-cell responses, and methods of using same | NOGRA PHARMA LIMITED (IE) | 2020-02-18 | — | — | US | disclosed |
| US-10208017-B2 | Heterocycles capable of modulating T-cell responses, and methods of using same | NOGRA PHARMA LIMITED (IE) | 2019-02-19 | — | — | US | disclosed |
| US-10208017-B2 | Heterocycles capable of modulating T-cell responses, and methods of using same | NOGRA PHARMA LIMITED (IE) | 2019-02-19 | — | — | US | disclosed |
| EP-2861563-B1 | BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LTD (IE) | 2017-07-12 | — | — | EP | disclosed |
| US-20170183313-A1 | BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LTD (IE) | 2017-06-29 | — | — | US | disclosed |
| US-20170183313-A1 | BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LTD (IE) | 2017-06-29 | — | — | US | disclosed |
| US-20160194303-A1 | HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2016-07-07 | — | — | US | disclosed |
| US-20160194303-A1 | HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2016-07-07 | — | — | US | disclosed |
| US-20160194303-A1 | HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2016-07-07 | — | — | US | disclosed |
| US-20150126553-A1 | BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2015-05-07 | — | — | US | disclosed |
| US-20150126553-A1 | BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2015-05-07 | — | — | US | disclosed |
| EP-2861575-A1 | HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | Nogra Pharma Limited (IE) | 2015-04-22 | — | — | EP | disclosed |
| WO-2013178816-A1 | HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2013-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126553-A1 | BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NFATC1, RORC, ICOS | PDE2A 706/4885ALDH1A1 492/4885NPSR1 2607/4885 |
| US-20160194303-A1 | HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | ICOS, NFATC1, CD74 | PDE2A 706/4885ALDH1A1 1481/4885NPSR1 2314/4885 |
| US-10562883-B2 | Heterocycles capable of modulating T-cell responses, and methods of using same | ICOS, NFATC1, CD74 | PDE2A 706/4885ALDH1A1 1481/4885NPSR1 2314/4885 |
| US-10208017-B2 | Heterocycles capable of modulating T-cell responses, and methods of using same | ICOS, NFATC1, CD74 | PDE2A 706/4885ALDH1A1 1481/4885NPSR1 2314/4885 |
| US-20170183313-A1 | BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NFATC1, RORC, ICOS | PDE2A 695/4885ALDH1A1 482/4885NPSR1 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.